AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 14.52 |
|---|---|
| Change | 0.000 0.000% |
| 52 W H/L (in USD) | 22.000/5.780 |
| EBITDA (in USD) | -49.425M |
| PE Ratio | -- |
| Volume | 107946 |
| Diluted Eps TTM | -0.96 |
| Total Assets (in USD) | 669.153M |
|---|---|
| Total Liabilities (in USD) | 188.798M |
| Revenue TTM (in USD) | 5.67M |
| Cash (in USD) | 62.563M |
| Market Cap (in USD) | 1,488.417 M |
| Revenue Per Share TTM | 0.050 |
| Gross Profit TTM (in USD) | -20.99M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Mesoblast Ltd
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.
Employees: 73
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) | Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director | 1957 |
| 2. | Dr. Eric A. Rose M.D. | Chief Medical Officer & Exec. Director | 1951 |
| 3. | Mr. Andrew Chaponnel B.Com. | Interim Chief Fin. Officer | NA |
| 4. | Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. | Chief Operating Officer | 1964 |
| 5. | Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) | Gen. Counsel & Corp. Exec. | 1968 |
| 6. | Mr. Roger D. Brown BA | Head of Spinal Orthopedic Disorders | NA |
| 7. | Mr. Michael Schuster M.B.A., MS, BSc, MBA | Head of Pharma Partnering | 1977 |
| 8. | Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA | Head of Regulatory Affairs & Quality Management | NA |
| 9. | Mr. Justin Horst B.S. | Head of Manufacturing | NA |
| 10. | Ms. Niva Sivakumar B.Com., L.L.B. | Joint Company Sec. | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -82.101M | -91.586M | -99.63M | -87.355M | -98.754M |
| Minority Interest | - | - | - | - | - |
| Net Income | -81.889M | -91.347M | -98.811M | -77.94M | -89.799M |
| Selling General Administrative | 25.374M | 27.21M | 30.867M | 25.609M | 21.625M |
| Gross Profit | 7.501M | 10.211M | 7.456M | 32.156M | 16.722M |
| Reconciled Depreciation | 4.107M | 4.38M | 4.264M | 3.667M | 2.139M |
| Ebit | -69.136M | -80.953M | -111.867M | -79.072M | -83.301M |
| Ebitda | -65.029M | -76.573M | -107.603M | -75.405M | -81.162M |
| Depreciation And Amortization | 4.107M | 4.38M | 4.264M | 3.667M | 2.139M |
| Operating Income | -69.136M | -80.953M | -111.867M | -79.072M | -83.301M |
| Other Operating Expenses | 76.79M | 90.785M | 115.059M | 107.561M | 97.884M |
| Interest Expense | 19.444M | 16.906M | 10.714M | 13.33M | 11.328M |
| Tax Provision | -0.212M | -0.239M | -0.819M | -9.415M | -8.955M |
| Interest Income | 0.831M | 0.003M | 0.022M | 0.542M | 0.719M |
| Net Interest Income | -19.291M | -17.285M | -10.714M | -14.716M | -11.704M |
| Income Tax Expense | -0.212M | -0.239M | -0.819M | -9.415M | -8.955M |
| Total Revenue | 7.501M | 10.211M | 7.456M | 32.156M | 16.722M |
| Total Operating Expenses | 76.79M | 90.785M | 115.059M | 107.561M | 97.884M |
| Cost Of Revenue | - | - | - | - | 15.358M |
| Total Other Income Expense Net | 6.479M | -10.633M | 12.237M | -8.283M | -15.453M |
| Net Income From Continuing Ops | -81.889M | -91.347M | -98.811M | -77.94M | -89.799M |
| Net Income Applicable To Common Shares | -81.889M | -91.347M | -98.811M | -77.94M | -89.799M |
Balance Sheet
(Currency in USD)| Breakdown | 30-06-2024 | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 |
|---|---|---|---|---|---|
| Total Assets | 669.153M | 669.415M | 662.142M | 744.717M | 733.602M |
| Intangible Assets | 441.283M | 442.73M | 444.199M | 446.093M | 447.148M |
| Other Current Assets | 2.551M | 1.421M | 5.4M | 11.346M | 7.22M |
| Total Liab | 188.798M | 167.577M | 165.098M | 163.32M | 184.276M |
| Total Stockholder Equity | 480.355M | 501.838M | 497.044M | 581.397M | 549.326M |
| Other Current Liab | 49.685M | 5.426M | 20.091M | 18.71M | 29.197M |
| Common Stock | 1310.813M | 1249.123M | 1165.309M | 1163.153M | 1051.45M |
| Capital Stock | 1310.813M | 1249.123M | 1165.309M | 1163.153M | 1051.45M |
| Retained Earnings | -908.761M | -820.805M | -738.916M | -647.569M | -548.758M |
| Good Will | 134.453M | 134.453M | 134.453M | 134.453M | 134.453M |
| Other Assets | - | 2.326M | 1.93M | 1.724M | 3.311M |
| Cash | 62.563M | 70.92M | 60.034M | 136.881M | 129.328M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 73.243M | 41.982M | 51.373M | 94.273M | 90.143M |
| Current Deferred Revenue | - | 6.399M | - | - | 23.449M |
| Net Debt | 56.36M | 45.575M | 46.871M | -31.386M | -30.014M |
| Short Term Debt | 16.488M | 10.012M | 8.203M | 55.965M | 35.974M |
| Short Long Term Debt | 13.862M | 5.952M | 5.017M | 53.2M | 32.455M |
| Short Long Term Debt Total | 118.923M | 116.495M | 106.905M | 105.495M | 99.314M |
| Other Stockholder Equity | - | 73.52M | 1235.96M | 1228.966M | 1098.084M |
| Property Plant Equipment | - | 6.491M | 9.965M | 12.14M | 10.271M |
| Total Current Assets | 86.463M | 81.658M | 69.837M | 148.227M | 136.548M |
| Long Term Investments | 1.014M | 1.757M | 1.758M | 2.08M | 1.871M |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 20.952M | 6.998M | 4.403M | 4.842M | 1.574M |
| Long Term Debt | 100.483M | 102.811M | 91.617M | 41.045M | 57.023M |
| Inventory | - | - | - | -4.842M | -1.574M |
| Accounts Payable | 7.07M | 20.145M | 23.079M | 19.598M | 24.972M |
| Accumulated Other Comprehensive Income | 78.303M | 73.52M | 70.651M | 65.813M | 46.634M |
| Non Currrent Assets Other | 2.102M | 0.481M | 1.93M | 1.724M | 3.311M |
| Non Current Assets Total | 582.69M | 587.757M | 592.305M | 596.49M | 597.054M |
| Capital Lease Obligations | 4.578M | 7.732M | 10.271M | 11.25M | 9.836M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | -0.194M | -0.232M | -1.647M | -3.273M | -1M |
| Total Cashflows From Investing Activities | -0.194M | -0.232M | -1.647M | -3.273M | -1M |
| Total Cash From Financing Activities | 74.502M | -9.87M | 114.466M | 137.044M | 71.608M |
| Net Income | -81.889M | -91.347M | -98.811M | -77.94M | -89.799M |
| Change In Cash | 10.871M | -76.434M | 7.553M | 78.902M | 12.663M |
| Begin Period Cash Flow | 60.447M | 136.881M | 129.328M | 50.426M | 37.763M |
| End Period Cash Flow | 71.318M | 60.447M | 136.881M | 129.328M | 50.426M |
| Total Cash From Operating Activities | -63.269M | -65.782M | -106.681M | -56.365M | -57.79M |
| Depreciation | 4.107M | 4.38M | 4.264M | 3.667M | 2.139M |
| Other Cashflows From Investing Activities | 0.12M | 0.12M | 0.12M | 0.12M | -0.721M |
| Dividends Paid | 0M | 0M | - | 0M | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | 30.258M |
| Other Cashflows From Financing Activities | -11.477M | 48.167M | 11.129M | -5.765M | 41.35M |
| Capital Expenditures | 0.314M | 0.232M | 1.647M | 2.246M | 0.279M |
| Change In Working Capital | -2.472M | 4.869M | -8.418M | 13.29M | 20.437M |
| Other Non Cash Items | 13.542M | 11.015M | -15.407M | 6.511M | 14.02M |
| Free Cash Flow | -63.583M | -66.014M | -108.328M | -58.611M | -58.069M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Biotechnology ETF | 1 year ago | 557935 |
| 2. | Fidelity Nasdaq Composite Index | 1 year ago | 18245 |
| 3. | iShares Nasdaq US Biotech ETF USD Acc | 1 year ago | 15982 |
| 4. | VT Downing Global Investors F Inc | 1 year ago | 12500 |
| 5. | ActivePassive International Equity ETF | 1 year ago | 8586 |
| 6. | China Universal NASDAQ Bio-Tch ETF(QDII) | 1 year ago | 6776 |
| 7. | Quantified Global Fund Investor | 1 year ago | 1409 |
| 8. | Invesco Nasdaq Biotechnology ETF | 1 year ago | 1382 |
| 9. | ProShares Ultra Nasdaq Biotechnology | 1 year ago | 1359 |
| 10. | DFA International Core Equity 2 I | 1 year ago | 796 |
| 11. | GF NASDAQ Bio-Tech Idx QDII RMB A | 1 year ago | 671 |
| 12. | Daiwa NASDAQ Biotech Index Mother Fund | 1 year ago | 105 |
| 13. | Morningstar Global Markets ADR | 1 year ago | 1 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 714928 |
| 2. | Morgan Stanley - Brokerage Accounts | 1 year ago | 402397 |
| 3. | Bank of America Corp | 1 year ago | 290728 |
| 4. | Goldman Sachs Group Inc | 1 year ago | 257143 |
| 5. | Summit X, LLC | 1 year ago | 198163 |
| 6. | Oaktree Capital Management LLC | 1 year ago | 179593 |
| 7. | UBS Group AG | 1 year ago | 168253 |
| 8. | Susquehanna International Group, LLP | 1 year ago | 153979 |
| 9. | Jane Street Group LLC | 1 year ago | 102175 |
| 10. | Penbrook Management LLC | 1 year ago | 87675 |
| 11. | Rockbridge Investment Management, LLC | 1 year ago | 49150 |
| 12. | Prosperity Wealth Management Inc | 1 year ago | 48700 |
| 13. | Oaktree Fund Advisors, LLC | 1 year ago | 47909 |
| 14. | Oasis Management Co. Ltd | 1 year ago | 41450 |
| 15. | LPL Financial Corp | 1 year ago | 40007 |
| 16. | Cubist Systematic Strategies, LLC | 1 year ago | 35191 |
| 17. | Citigroup Inc | 1 year ago | 25497 |
| 18. | Creative Planning Inc | 1 year ago | 24873 |
| 19. | Pine Valley Investments Ltd Liability Co | 1 year ago | 20931 |
| 20. | Thoroughbred Financial Services, LLC | 1 year ago | 20718 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...